摘要
目的探究沙库巴曲缬沙坦治疗射血分数降低的心力衰竭(HFrEF)患者临床效果及对超声心动图参数和血清Nexilin、可溶性致癌抑制因子2(sST2)水平的影响。方法选取2020年3月—2021年3月上海交通大学医学院附属新华医院崇明分院门诊收治的112例HFrEF患者,采用随机数字表法分为对照组和研究组,各56例。两组均行常规治疗,于此基础上对照组采用贝那普利治疗,研究组采用沙库巴曲缬沙坦治疗,均持续治疗3个月。比较两组治疗效果、不良反应发生率、治疗前后超声心动图参数[左室射血分数(LVEF)、左心房内径(LA)、左心室舒张末期内径(LVEDD)]、心功能(NYHA分级)、血清半乳糖凝集素3(Gal-3)、Nexilin、可溶性致癌抑制因子2(sST2)水平及生活质量(MLHFQ评分)、运动耐力(6MWD)。结果研究组治疗总有效率(82.14%)高于对照组(64.29%)(P<0.05);研究组治疗后LVEF高于对照组,LA、LVEDD低于对照组(P<0.05);治疗后,研究组心功能NYHA分级优于对照组(P<0.05);研究组治疗后血清Gal-3、Nexilin、sST2水平均低于对照组(P<0.05);治疗后,研究组MLHFQ评分低于对照组,6MWD高于对照组(P<0.05);研究组不良反应发生率(23.21%)与对照组(26.79%)比较,差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦治疗HFrEF患者临床效果良好,能明显改善患者超声心动图参数,进一步下调血清Gal-3、Nexilin、sST2水平,显著改善患者预后。
Objective To explore the clinical effect of sacubitril and valsartan in the treatment of patients with heart failure with reduced ejection fraction(HFrEF)and its effect on echocardiographic parameters,serum Nexilin,and soluble carcinogenic inhibitor 2(sST2)levels.Methods A total of 112 patients with HFrEF admitted to our hospital from March 2020 to March 2021 were divided into control group and study group by random number table,with 56 cases in each group.Both groups received conventional treatment.On this basis,the control group was treated with benazepril,and the study group was treated with sacubitril and valsartan,and the treatment was continued for 3 months.Comparison of treatment effects,incidence of adverse reactions,echocardiographic parameters before and after treatment[left ventricular ejection fraction(LVEF),left atrial diameter(LA),left ventricular end diastolic diameter(LVEDD)],cardiac function(NYHA classification),Serum galectin 3(Gal-3),Nexilin,soluble carcinogenic inhibitor 2(sST2)levels,quality of life(MLHFQ score),exercise endurance(6 MWD).Results The total effective rate of treatment in the study group(82.14%)was higher than that of the control group(64.29%)(P<0.05);the LVEF of the study group after treatment was higher than that of the control group,and LA and LVEDD were lower than the control group(P<0.05);after that,the NYHA classification of heart function in the study group was better than that of the control group(P<0.05);the serum levels of Gal-3,Nexilin,and sST2 in the study group after treatment were lower than those in the control group(P<0.05);after treatment,the study group had a low MLHFQ score;In the control group,6MWD was higher than that in the control group(P<0.05);the adverse reaction rate in the study group(23.21%)was compared with that in the control group(26.79%),and the difference was not statistically significant(P>0.05).Conclusion The clinical effect of sacubitril and valsartan in the treatment of HFrEF patients is good.It can significantly improve the echocardiographic
作者
袁玉敏
宋蕾
李桂茹
岳冬梅
YUAN Yumin;SONG Lei;LI Guiru;YUE Dongmei(Chongming Branch of Xinhua Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 202150,China)
出处
《中国急救复苏与灾害医学杂志》
2022年第11期1413-1416,共4页
China Journal of Emergency Resuscitation and Disaster Medicine
基金
上海市卫生系统优秀青年医学人才培养项目(编号:PWRq2018-37)。
